Overview

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Status:
Unknown status
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, one-arm, multi-site trial PDT-ALL-LBL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide for adult T-ALL/LBL. Compared to PDT-ALL-2016 for B-ALL, HDACi chidamide will be administrated from induction therapy to maintenance therapy, along with higher dose of consolidation regimen of cytarabine, methotrexate, cyclophosphamide.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Treatments:
6-Mercaptopurine
BB 1101
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone acetate
Doxorubicin
Etoposide
Etoposide phosphate
Histone Deacetylase Inhibitors
Idarubicin
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Pegaspargase
Vincristine